Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of March 2026, with a specific reporting date of March 25, 2026. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a specific securities transaction rather than a financial results report.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADS) |
| Instrument ISIN | US37733W2044 |
| Transaction Price | $51.9900 |
| Transaction Volume | 6.679 ADS |
| Transaction Date | March 23, 2026 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single acquisition of notional ADS within the GSK Executive Supplemental Savings Plan account for Maya Martinez-Davis, President of the US region.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It includes a standard corporate description stating GSK is a global biopharma company focused on uniting science, technology, and talent to address disease.
Key Facts for Investor Verification
- Verify the identity of the insider: Maya Martinez-Davis, President, US.
- Confirm the transaction was an acquisition of 6.679 ADS at $51.99 per share on March 23, 2026.
- Note that the transaction occurred within an Executive Supplemental Savings Plan account.
- Understand that this filing does not contain quarterly or annual financial results.